Adage Capital Partners’s Enliven Therapeutics ELVN Stock Holding History

Adage Capital Partners’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55M	Buy	+1,083,313	New	+$46M	0.08%	259
2025 Q4	–	Sell	-73,000	Closed	-$1.49M	–	941
2025 Q3	$1.49M	Sell	73,000 -23,000	-24%	-$464K	﹤0.01%	823
2025 Q2	$1.93M	Sell	96,000 -354,000	-79%	-$6.7M	﹤0.01%	762
2025 Q1	$8.86M	Sell	450,000 -200,000	-31%	-$4.3M	0.02%	610
2024 Q4	$14.6M	Sell	650,000 -150,000	-19%	-$3.89M	0.03%	512
2024 Q3	$20.4M	Sell	800,000 -40,000	-5%	-$926K	0.04%	443
2024 Q2	$19.6M	Buy	+840,000	New	+$17.7M	0.04%	441

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Adage Capital Partners's ELVN Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 1,083,313 shares worth $55M. The stake represents 0.08% of the portfolio and ranks #259 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in ELVN as recently as Q3 2025.

Adage Capital Partners first reported a position in ELVN in Q2 2024 and has held it in 7 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Adage Capital Partners held 1,083,313 shares of Enliven Therapeutics worth $55M as of Q2 2026.
Enliven Therapeutics was a new Adage Capital Partners position in Q2 2026.
Enliven Therapeutics made up 0.08% of Adage Capital Partners's portfolio in Q2 2026, its #259 holding.
Adage Capital Partners first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 7 quarters since.
213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.